Role of trabectedin in the treatment of soft tissue sarcoma.

Interest in marine natural products has allowed the discovery of new drugs and trabectedin (ET-743, Yondelis), derived from the marine tunicate Ecteinascidia turbinata, was approved for clinical use in 2007. It binds to the DNA minor groove leading to interferences with the intracellular transcription pathways and DNA-repair proteins. In vitro antitumor activity was demonstrated against various cancer cell lines and soft tissue sarcoma cell lines. In phase I studies tumor responses were observed also in osteosarcomas and different soft tissue sarcoma subtypes. The most common toxicities were myelosuppression and transient elevation of liver function tests, which could be reduced by dexamethasone premedication. The efficacy of trabectedin was established in three phase II studies where it was administered at 1.5 mg/m2 as a 24 h intravenous infusion repeated every three weeks, in previously treated patients. The objective response rate was 3.7%-8.3% and the tumor control rate (which included complete response, partial response and stable disease) was obtained in half of patients for a median overall survival reaching 12 months. In nonpretreated patients the overall response rate was 17%. Twenty-four percent of patients were without progression at six months. The median overall survival was almost 16 months with 72% surviving at one year. Predictive factors of response are being explored to identify patients who are most likely to respond to trabectedin. Combination with other agents are currently studied with promising results. In summary trabectedin is an active new chemotherapeutic agents that has demonstrated its role in the armamentarium of treatments for patients with sarcomas.

Optimization of energy consumption in wastewater pumping

Pumppauksessa arvioidaan olevan niin teknisesti kuin taloudellisestikin huomattavia mahdollisuuksia säästää energiaa. Maailmanlaajuisesti pumppaus kuluttaa lähes 22 % sähkö-moottorien energiantarpeesta. Tietyillä teollisuudenaloilla jopa yli 50 % moottorien käyttämästä sähköenergiasta voi kulua pumppaukseen. Jäteveden pumppauksessa pumppujen toiminta perustuu tyypillisesti on-off käyntiin, jolloin pumpun ollessa päällä se käy täydellä teholla. Monissa tapauksissa pumput ovat myös ylimitoitettuja. Yhdessä nämä seikat johtavat kasvaneeseen energian kulutukseen. Työn teoriaosassa esitellään perusteet jätevesihuollosta ja jäteveden käsittelystä sekä pumppaussysteemin pääkomponentit: pumppu, putkisto, moottori ja taajuusmuuttaja. Työn empiirisessä osassa esitellään työn aikana kehitetty laskuri, jonka avulla voidaan arvioida energiansäästöpotentiaalia jäteveden pumppaussysteemeissä. Laskurilla on mandollista laskea energiansäästöpotentiaali käytettäessä pumpun tuoton ohjaustapana pyörimisnopeuden säätöä taajuusmuuttajalla on-off säädön sijasta. Laskuri ilmoittaa optimaalisimmanpumpun pyörimisnopeuden sekä ominaisenergiankulutuksen. Perustuen laskuriin, kolme kunnallista jätevedenpumppaamoa tutkittiin. Myös laboratorio-testitsuoritettiin laskurin simuloimiseksi sekä energiansäästöpotentiaalin arvioimiseksi. Tutkimukset osoittavat, että jätevedenpumppauksessa on huomattavia mandollisuuksia säästää energiaa pumpun pyörimisnopeutta pienentämällä. Geodeettisen nostokorkeuden ollessa pieni, voidaan energiaa säästää jopa 50 % ja pitkällä aikavälillä säästö voi olla merkittävä. Tulokset vahvistavat myös tarpeen jätevedenpumppaussysteemien toiminnan optimoimiseksi.

Early high-dose treatment: SCT results from the European High Risk Neuroblastoma Study

Aims: The HR-NBL1 Study of the European SIOP Neuroblastoma Group (SIOPEN) randomised two high dose regimens to learn about potential superiority and toxicity profiles.Patients and Methods: At interim analysis 1483 high risk neuroblastoma patients (893 males) were included since 2002 with either INSS stage 4 disease (1383 pts) above 1 year, or as infants (59 pts) and stage 2&3 of any age (145 pts) with MYCN amplification. The median age at diagnosis was 2.9 years (1 month-19.9 years) with a median follow up of 3 years. Response eligibility criteria prior randomisation after Rapid Cojec Induction (J Clin Oncol, 2010) ± 2 courses of TVD (Cancer, 2003) included complete bone marrow remission and at least partial response at skeletal sites with no more than 3, but improved mIBG positive spots and a PBSC harvest of at least 3x10E6 CD34/kgBW. The randomised regimens were BuMel [busulfan oral till 2006, 4x150mg/m² in 4 ED; or intravenous use according to body weight as licenced thereafter; melphalan 140mg/m²/day) and CEM [carboplatinum ctn. infusion (4x AUC 4.1mg/ml.min/day, etoposid ctn. infusion (4x 338mg/m²/day or [4x 200mg/m²/day]*, melphalan (3x70mg/m²/day; 3x60mg/m²/day*;*reduced dosis if GFR< 100ml/min/1.73m²). Supportive care followed institutional guidelines. VOD prophylaxis included ursadiol, but randomised patients were not eligible for the prophylactic defibrotide trial. Local control included surgery and radiotherapy of 21Gy.Results: Of 1483 patients, 584 were being randomised for the high dose question at data lock. A significant difference in event free survival (3-year EFS 49% vs. 33%, p<0.001) and overall survival (3-year OS 61% vs. 48%, p=0.003) favouring the BuMel regimen over the CEM regimen was demonstrated. The relapse/progression rate was significantly higher after CEM (0.60±0.03) than after BuMel (0.48±0.03)(p<0.001). Toxicity data had reached 80% completeness at last analysis. The severe toxicity rate up to day 100 (ICU and toxic deaths) was below 10%, but was significantly higher for CEM (p= 0.014). The acute toxic death rate was 3% for BuMel and 5% for CEM (NS). The acute HDT toxicity profile favours the BuMel regimen in spite of a total VOD incidence of 18% (grade 3:5%).Conclusions: The Peto rule of P<0.001 at interim analysis on the primary endpoint, EFS was met. Hence randomization was stopped with BuMel as recommended standard treatment in the HR-NBl1/SIOPEN trial which is still accruing for the randomised immunotherapy question.

Laskentamalli PKL-koelaitteiston pienen vuodon kokeen simuloimiseksi Apros-ohjelmistolla

Työn tavoitteena oli tehdä Apros-laskentamalli PKL-koelaitteistosta ja testata kuinka hyvin Apros pystyy laskemaan PKL-koelaitteistolla suoritetun E2.2 pienen vuodon kokeen. Tavoitteena oli myös tarkastella boorittoman veden tulpan etenemistä pienen vuodon kokeen aikana. PKL-koelaitteisto vastaa saksalaista sähköteholtaan 1300 MW olevaa Philippsburg 2 painevesilaitosta. Koelaitteiston tilavuudet ja teho on skaalattu kertoimella 145. Työssä tehdyllä laskentamallilla tarkasteltiin boorittoman veden tulpan liikkumista pienen vuodon kokeen aikana. Kun malli oli valmis, laskenta suoritettiin Apros 5.05 versiolla. Boorittoman veden tulpan etenemisen laskennassa käytettiin toisen kertaluvun diskretointia, jolla booripitoisuuden muutokset säilyvät teräväreunaisina. Laskentamalli pystyi kuvaamaan koelaitteistolla suoritetussa pienen vuodon kokeessa tapahtuneet ilmiöt varsin hyvin. Eroa koetuloksiintuli pääkiertopiirien luonnonkiertojen alkamishetkistä ja primääripaineen käyttäytymisessä. Kokeen alkutilanne ei ollut stationääritila, joten alkutilanteen asettamisessa oli hankaluuksia. Varsinkin pääkiertopiirien veden pinnankorkeuksienasettamisessa oli vaikeuksia, koska veden pinnankorkeuksien erot pyrkivät tasoittumaan nopeasti kokeen aikana. Apros pystyi laskemaan PKL-koelaitteistolla suoritetun pienen vuodon kokeen hyvin. Mallilla tulisi kuitenkin laskea vielä toisentyyppisiäkin kokeita, ennen kuin voidaan varmuudella tietää mallin toimivuus. PKL-koelaitteisto vastaa pääpiirteiltään Suomeen rakennettavaa Olkiluoto 3 ydinvoimalaitosta. Tehty työ antaa lisävarmuutta, kun Olkiluoto 3 laitoksen turvallisuustarkasteluita tehdään.

Four-hour infusions of synthetic atrial natriuretic peptide in normal volunteers.

Two doses of synthetic atrial natriuretic peptide (0.5 and 5.0 micrograms/min) and its vehicle were infused intravenously for 4 hours in eight salt-loaded normal volunteers, and the effect on blood pressure, heart rate, renal hemodynamics, solute excretion, and secretion of vasoactive hormones was studied. The 0.5 micrograms/min infusion did not alter blood pressure or heart rate, whereas the 5.0 micrograms/min infusion significantly reduced the mean pressure by 20/9 mm Hg after 2.5 to 3 hours and increased the heart rate slightly. Inulin clearance was not significantly changed, but the mean p-aminohippurate clearance fell by 13 and 32% with the lower and higher doses, respectively. Urinary excretion of sodium and chloride increased slightly with the lower dose. With the higher dose, a marked increase in urinary excretion of sodium, chloride, and calcium was observed, reaching a peak during the second hour of the infusion. Potassium and phosphate excretion did not change significantly. A brisk increase in urine flow rate and fractional water excretion was seen only during the first hour of the high-dose infusion. Signs and symptoms of hypotension were observed in two subjects. No change in plasma renin activity, angiotensin II, or aldosterone was observed during either infusion, but a marked increase occurred after discontinuation of the high-dose infusion. In conclusion, the 5 micrograms/min infusion induced a transient diuretic effect, delayed maximal natriuretic activity, and a late fall in blood pressure, with no change in inulin clearance but a dose-related decrease in p-aminohippurate clearance. Despite large amounts of sodium excreted and blood pressure reduction, no counterregulatory changes were observed in the renin-angiotensin-aldosterone system or plasma vasopressin levels during the infusion.

Effect of Noncondensable Gases on Circulation of Primary Coolant in Nuclear Power Plants in Abnormal Situations

The present study focuses on two effects of the presence of a noncondensable gas on the thermal-hydraulic behavior of thecoolant of the primary circuit of a nuclear reactor in the VVER-440 geometry inabnormal situations. First, steam condensation with the presence of air was studied in the horizontal tubes of the steam generator (SG) of the PACTEL test facility. The French thermal-hydraulic CATHARE code was used to study the heat transfer between the primary and secondary side in conditions derived from preliminary experiments performed by VTT using PACTEL. In natural circulation and single-phase vapor conditions, the injection of a volume of air, equivalent to the totalvolume of the primary side of the SG at the entrance of the hot collector, did not stop the heat transfer from the primary to the secondary side. The calculated results indicate that air is located in the second half-length (from the mid-length of the tubes to the cold collector) in all the tubes of the steam generator The hot collector remained full of steam during the transient. Secondly, the potential release of the nitrogen gas dissolved in the water of the accumulators of the emergency core coolant system of the Loviisa nuclear power plant (NPP) was investigated. The author implemented a model of the dissolution and release ofnitrogen gas in the CATHARE code; the model created by the CATHARE developers. In collaboration with VTT, an analytical experiment was performed with some components of PACTEL to determine, in particular, the value of the release time constant of the nitrogen gas in the depressurization conditions representative of the small and intermediate break transients postulated for the Loviisa NPP. Such transients, with simplified operating procedures, were calculated using the modified CATHARE code for various values of the release time constant used in the dissolution and release model. For the small breaks, nitrogen gas is trapped in thecollectors of the SGs in rather large proportions. There, the levels oscillate until the actuation of the low-pressure injection pumps (LPIS) that refill the primary circuit. In the case of the intermediate breaks, most of the nitrogen gas is expelled at the break and almost no nitrogen gas is trapped in the SGs. In comparison with the cases calculated without taking into account the release of nitrogen gas, the start of the LPIS is delayed by between 1 and 1.75 h. Applicability of the obtained results to the real safety conditions must take into accountthe real operating procedures used in the nuclear power plant.

Correlations of glycogen synthase and phosphorylase activities with glycogen concentration in human muscle biopsies. Evidence for a double-feedback mechanism regulating glycogen synthesis and breakdown.

The purpose of this study was to verify in man the relationships of muscle glycogen synthase and phosphorylase activities with glycogen concentration that were reported in animal studies. The upper level of glycogen concentration in muscle is known to be tightly controlled, and glycogen concentration was reported to have an inhibitory effect on synthase activity and a stimulatory effect on phosphorylase activity. Glycogen synthase and phosphorylase activity and glycogen concentration were measured in muscle biopsies in a group of nine normal subjects after stimulating an increase of their muscle glycogen concentration through either an intravenous glucose-insulin infusion to stimulate glycogen synthesis, or an Intralipid (Vitrum, Stockholm, Sweden) infusion in the basal state to inhibit glycogen mobilization by favoring lipid oxidation at the expense of glucose oxidation. Phosphorylase activity increased from 71.3 +/- 21.0 to 152.8 +/- 20.0 nmol/min/mg protein (P < .005) after the glucose-insulin infusion. Phosphorylase activity was positively correlated with glycogen concentration (P = .005 and P = .0001) after the glucose-insulin and Intralipid infusions, respectively. Insulin-stimulated glycogen synthase activity was significantly negatively correlated with glycogen concentration at the end of the Intralipid infusion (P < .005). In conclusion, by demonstrating a negative correlation of glycogen concentration with glycogen synthase and a positive correlation with phosphorylase, this study might confirm in man the double-feedback mechanism by which changes in glycogen concentration regulate glycogen synthase and phosphorylase activities. It suggests that this mechanism might play an important role in the regulation of glucose storage.

Assessment of metabolic fluxes in the mouse brain in vivo using 1H-[13C] NMR spectroscopy at 14.1 Tesla.

(13)C magnetic resonance spectroscopy (MRS) combined with the administration of (13)C labeled substrates uniquely allows to measure metabolic fluxes in vivo in the brain of humans and rats. The extension to mouse models may provide exclusive prospect for the investigation of models of human diseases. In the present study, the short-echo-time (TE) full-sensitivity (1)H-[(13)C] MRS sequence combined with high magnetic field (14.1 T) and infusion of [U-(13)C6] glucose was used to enhance the experimental sensitivity in vivo in the mouse brain and the (13)C turnover curves of glutamate C4, glutamine C4, glutamate+glutamine C3, aspartate C2, lactate C3, alanine C3, γ-aminobutyric acid C2, C3 and C4 were obtained. A one-compartment model was used to fit (13)C turnover curves and resulted in values of metabolic fluxes including the tricarboxylic acid (TCA) cycle flux VTCA (1.05 ± 0.04 μmol/g per minute), the exchange flux between 2-oxoglutarate and glutamate Vx (0.48 ± 0.02 μmol/g per minute), the glutamate-glutamine exchange rate V(gln) (0.20 ± 0.02 μmol/g per minute), the pyruvate dilution factor K(dil) (0.82 ± 0.01), and the ratio for the lactate conversion rate and the alanine conversion rate V(Lac)/V(Ala) (10 ± 2). This study opens the prospect of studying transgenic mouse models of brain pathologies.

Pumpunvalitsimet integroidussa simulointiympäristössä

Työssä on tutkittu pumpun valintaa integroidussa simulointiympäristössä. Tutkimuksen avulla on tarkoitus kehittää tieto- ja malligallerian (Galleria) infrastuktuuria ja käytössä olevia työvälineitä siihen suuntaan, että ulkoisten valitsinkomponenttien implementoiminen Gallerian tietokantaan olisi lähitulevaisuudessa helppoa ja nopeaa. Prosessi-integraation tieto- ja malligalleria on infrastruktuurimäärittely ja työvälineistö prosessikomponenttien ja osaprosessien simulointiin tarvittavien malli- ja parametritietojen kirjastoimiseksi internetpohjaiseen tietokantaan, josta ne ovat simulointiohjelmien käyttäjien ja muiden prosessisuunnittelijoiden helposti saatavilla. Tutkimuksen kirjallisessa osassa on keskitytty tutkimaan pumpun valinnan etenemistä ja valintaan vaikuttavia tekijöitä prosessisuunnittelijan näkökulmasta. Tutkimuksen soveltavassa osassa luotiin pumpunvalitsin ja sitä testattiiin Galleria- ympäristöä vastaavassa kehitysympäristössä. Pumpunvalitsimen kehittämisessä on käytetty apuna laitevalmistajalta saatua prosessikomponenttitietoa. Pumpunvalitsimen toteutus perustuu pumpun hydrauliseen valintaan ja esimerkkitapauksena käytettiin keskipakopumppua

Logistics in Pump Manufacturer's Spare Part Distribution Network

Tässä diplomityössä käsitellään pumppujen maailmanlaajuista varaosa-jakelua. Työn pääpaino on varaosien moniportaisen jakeluverkon toimitusketjun logistiikassa. Asiakaspalvelussa varaosien nopea saatavuus on ratkaisevassa asemassa, jotta asiakkaiden tehtaiden käynnissäpito voidaan turvata. Työn tavoitteena oli kehittää Ahlström Pumpuille uusi globaali toimintamalli varaosien jakeluun. Tämä uusi varaosien jakelumalli on kehitetty pääasiassa sopimusasiakkaille, jotka ovat halukkaita ulkoistamaan varaosatoimintonsa. Mallia sovelletaan käytäntöön varaosien jakelussa ensiksi Suomessa ja Ruotsissa. Myöhemmin on tarkoitus kopioida mallia myös muualle. Malli on pyritty rakentamaan siten, että siihen voidaan helposti liittää muita Ahlström Pumppujen tarjoamia palveluita. Työssä koottu materiaali perustuu pääasiassa haastatteluihin, palavereihin, erilaisiin sisäisiin raportteihin, kirjallisuuteen ja itsenäiseen selvitystyöhön. Työssä on myös tutustuttu kolmen eri yrityksen after-sales- ja varaosatoimintaan.

Euron käyttöönoton hallinta keskisuuressa yrityksessä

Työn tavoitteena oli laatia euron käyttöönottosuunnitelma. Ensin selvitettiin euron syntyvaiheet ja yhteisen valuutan käsittelysäännöt. Sen jälkeen käydään läpi eräs käyttökelpoinen suunnitelma euron käyttöönottamiseksi, johon kuuluu euron käyttöönoton and speed up the implementation of external selection components. Model and Parametrisation Gallery for Process Integration is specification of an infrastructure and a set of tools which are built for storing process component and model library data into an internet based database from where it can be easily used by simulator users and other process designers. This work consists of two parts. In the literature survey pump selection and the factors that affects selection particularly on process designers point of view are studied. In the applied part a pump selector was created and tested in the test environment which is comparable to Gallery environment. This was done to ease the deployment of the selector to the actual working environment. Process component data of a manufacturer was used on the development of the pump selector. The execution of the selector is based on the hydraulic selection of pumps. Centrifugal pump was used as an example case.

A phase IIa randomised clinical study of GNbAC1, a humanised monoclonal antibody against the envelope protein of multiple sclerosis-associated endogenous retrovirus in multiple sclerosis patients.

BACKGROUND: GNbAC1 is an immunoglobulin (IgG4) humanised monoclonal antibody against multiple sclerosis-associated retrovirus (MSRV)-Env, a protein of endogenous retroviral origin, expressed in multiple sclerosis (MS) lesions, which is pro-inflammatory and inhibits oligodendrocyte precursor cell differentiation. OBJECTIVE: This is a randomised, double-blind placebo-controlled dose-escalation study followed by a six-month open-label phase to test GNbAC1 in MS patients. The primary objective was to assess GNbAC1 safety in MS patients, and the other objectives were pharmacokinetic and pharmacodynamic assessments. METHODS: Ten MS patients were randomised into two cohorts to receive a single intravenous infusion of GNbAC1/placebo at doses of 2 or 6 mg/kg. Then all patients received five infusions of GNbAC1 at 2 or 6 mg/kg at four-week intervals in an open-label setting. Safety, brain magnetic resonance imaging (MRI), pharmacokinetics, immunogenicity, cytokines and MSRV RNA expression were studied. RESULTS: All patients completed the study. GNbAC1 was well tolerated in all patients. GNbAC1 pharmacokinetics is dose-linear with mean elimination half-life of 27-37 d. Anti-GNbAC1 antibodies were not detected. Cytokine analysis did not indicate an adverse effect. MSRV-transcripts showed a decline after the start of treatment. Nine patients had stable brain lesions at MRI. CONCLUSION: The safety, pharmacokinetic profile, and pharmacodynamic responses to GNbAC1 are favourable in MS patients over a six-month treatment period.

Novel micropatterns mechanically control fibrotic reactions at the surface of silicone implants.

Over the past decade, various implantable devices have been developed to treat diseases that were previously difficult to manage such diabetes, chronic pain, and neurodegenerative disorders. However, translation of these novel technologies into clinical practice is often difficult because fibrotic encapsulation and/or rejection impairs device function after body implantation. Ideally, cells of the host tissue should perceive the surface of the implant being similar to the normal extracellular matrix. Here, we developed an innovative approach to provide implant surfaces with adhesive protein micropatterns. The patterns were designed to promote adhesion of fibroblasts and macrophages by simultaneously suppressing fibrogenic activation of both cell types. In a rat model, subcutaneously implanted silicone pads provided with the novel micropatterns caused 6-fold lower formation of inflammatory giant cells compared with clinical grade, uncoated, or collagen-coated silicone implants. We further show that micropatterning of implants resulted in 2-3-fold reduced numbers of pro-fibrotic myofibroblast by inhibiting their mechanical activation. Our novel approach allows controlled cell attachment to implant surfaces, representing a critical advance for enhanced biointegration of implantable medical devices.

Coronary vasomotor responses to isometric handgrip exercise are primarily mediated by nitric oxide: a noninvasive MRI test of coronary endothelial function.

Endothelial cell release of nitric oxide (NO) is a defining characteristic of nondiseased arteries, and abnormal endothelial NO release is both a marker of early atherosclerosis and a predictor of its progression and future events. Healthy coronaries respond to endothelial-dependent stressors with vasodilatation and increased coronary blood flow (CBF), but those with endothelial dysfunction respond with paradoxical vasoconstriction and reduced CBF. Recently, coronary MRI and isometric handgrip exercise (IHE) were reported to noninvasively quantify coronary endothelial function (CEF). However, it is not known whether the coronary response to IHE is actually mediated by NO and/or whether it is reproducible over weeks. To determine the contribution of NO, we studied the coronary response to IHE before and during infusion of N(G)-monomethyl-l-arginine (l-NMMA, 0.3 mg·kg(-1)·min(-1)), a NO-synthase inhibitor, in healthy volunteers. For reproducibility, we performed two MRI-IHE studies ∼8 wk apart in healthy subjects and patients with coronary artery disease (CAD). Changes from rest to IHE in coronary cross-sectional area (%CSA) and diastolic CBF (%CBF) were quantified. l-NMMA completely blocked normal coronary vasodilation during IHE [%CSA, 12.9 ± 2.5 (mean ± SE, placebo) vs. -0.3 ± 1.6% (l-NMMA); P < 0.001] and significantly blunted the increase in flow [%CBF, 47.7 ± 6.4 (placebo) vs. 10.6 ± 4.6% (l-NMMA); P < 0.001]. MRI-IHE measures obtained weeks apart strongly correlated for CSA (P < 0.0001) and CBF (P < 0.01). In conclusion, the normal human coronary vasoactive response to IHE is primarily mediated by NO. This noninvasive, reproducible MRI-IHE exam of NO-mediated CEF promises to be useful for studying CAD pathogenesis in low-risk populations and for evaluating translational strategies designed to alter CAD in patients.

Advanced control methods for reducing nitrogen oxides in a fluidized bed boiler

Tämän työn tarkoituksena oli löytää keinoja erään leijukerroskattilan typenoksidipäästöjen vähentämiseksi. Koska päästöt olivat jo alunperin alhaiset leijukerrostekniikan ja hybridin SNCR/SCR –typenpoistolaitteiston ansiosta, päätettiin päästöjä lähteä vähentämään parantamalla ammoniakkiruiskutuksen säätöä. Alkuperäinen ammoniakkiruiskutuksen säätö oli liian hidas, jotta satunnaisten häiriöiden aiheuttamat typenoksidipiikit olisi pystytty poistamaan. Ammoniakkiruiskutusta parannettiin lisäämällä jokaiseen ammoniakkilinjaan mäntäpumput, joiden avulla ammoniakkia voidaan syöttää sinne, missä sitä eniten tarvitaan. Ammoniakkiruiskutuksen säätöön kehitettiin uusi sumeaan logiikkaan perustuva säätäjä. Myös muita kehittyneitä säätömenetelmiä kuten neuroverkkoa hyödynnettiin säätäjän kehityksessä. Ammoniakkiruiskutuksen säätäjää testattiin menestyksekkäästi Ruotsissa Brista Kraftin Märstassa sijaitsevalla voimalaitoksella